Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
| ▸ | CASP2 | P42575 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
| ▸ | CASP6 | P55212 | 1/20 | 0.30 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5393650 | 0.66 | GSK3B (0.48) | PARP1GSK3BIDO1MAP2K1MAPT | |
| SCHEMBL24783216 | 0.64 | CDC7 (0.33) | PARP1MAPT | |
| SCHEMBL21296775 | 0.64 | GSK3B (0.52) | PARP1GSK3BMAPTCASP3CASP2 | |
| SCHEMBL555451 | 0.64 | GSK3B (0.52) | PARP1GSK3BMAPTCASP3CASP2 | |
| SCHEMBL2424580 | 0.63 | MAP2K1 (0.41) | PARP1GSK3BIDO1MAP2K1MAPT | |
| SCHEMBL21296739 | 0.62 | GSK3B (0.34) | GSK3BCASP3CASP2CASP7CASP6 | |
| SCHEMBL7847706 | 0.62 | — | — | |
| SCHEMBL1072291 | 0.60 | IDO1 (0.36) | IDO1MAP2K1MAPT | |
| SCHEMBL3276747 | 0.58 | TDP2 (0.47) | PARP1MAP2K1CASP3CASP7CASP6 | |
| SCHEMBL1887298 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530181-B2 | IL-6 inhibitors and methods of treatment | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-12-20 | — | — | US | claimed |
| US-11530181-B2 | IL-6 inhibitors and methods of treatment | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210206718-A1 | IL-6 INHIBITORS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2021-07-08 | — | — | US | disclosed |
| WO-2019165158-A1 | IL-6 INHIBITORS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530181-B2 | IL-6 inhibitors and methods of treatment | IL6, IL6ST, IL2 | PARP1 3465/4885GSK3B 1419/4885IDO1 297/4885 |
| US-20210206718-A1 | IL-6 INHIBITORS AND METHODS OF TREATMENT | IL6, IL6ST, IL2 | PARP1 3465/4885GSK3B 1419/4885IDO1 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.